Loading…
Federal Initiative to Guarantee Health by Targeting Fentanyl Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Federal Initiative to Guarantee Health by Targeting Fentanyl Act This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Additionally, the bill prohibits the application of a mandatory minimum prison term for certain drug offenses involving fentanyl-related substances.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2025 · third_quarter · Medicare/Medicaid
H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act S. 339, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act - To amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $1,700,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2022 · fourth_quarter · Health Issues
H.R.8295/S.4659, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2023, Provisions relating to NIH, Substance Use Research Barriers to research resulting from DEA scheduling, Drug research related issues Public Law 117-215, Cannabidiol & Marijuana Research Expansion Act, Drug use research related issues H.R.1910, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.2366, Support, Treatment and Overdose Prevention of Fentanyl Act H.R.2405, Streamlining Research on Controlled Substances Act H.R.2430, To amend the Temporary Reauthorization and Study of Emergency Scheduling of Fentanyl Analogues Act to extend for one year the temporary order for fentanyl-related substances S.339, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.4591, Cannabis Administration and Opportunity Act, Drug use research H.R.6184/S.3336, HALT Fentanyl Act, Drug use research related issues Public Law 117-328, Consolidated Appropriations Act, FY2023, Provisions related to NIH and Substance use research Monitor H.R.6946, SAFE Act of 2022, Drug use research related issues
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2022 · third_quarter · Health Issues
H.R.8295/S.4659, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2023, Provisions relating to NIH, Substance Use Research H.R.2630, Extending Temporary Emergency Scheduling of Fentanyl Analogues Act Barriers to research resulting from DEA scheduling, Drug research related issues H.R.8454/S.253, Cannabidiol & Marijuana Research Expansion Act, Drug use research related issues H.R.1910, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.2366, Support, Treatment and Overdose Prevention of Fentanyl Act H.R.2405, Streamlining Research on Controlled Substances Act H.R.2430, To amend the Temporary Reauthorization and Study of Emergency Scheduling of Fentanyl Analogues Act to extend for one year the temporary order for fentanyl-related substances S.339, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.4591, Cannabis Administration and Opportunity Act, Drug use research H.R.6184/S.3336, HALT Fentanyl Act, Drug use research related issues H.R.6946, SAFE Act of 2022, Drug use research related issues Monitor Public Law 117-70, Extending Temporary Emergency Scheduling of Fentanyl Analogues Act, Drug use research related issues
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2022 · second_quarter · Health Issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2023, Provisions relating to NIH, Substance Use Research Barriers to research resulting from DEA scheduling, Drug research related issues S.253, Cannabidiol & Marijuana Research Expansion Act, Drug use research related issues H.R.5657, Medical Marijuana Research Act, Drug use research related issues H.R.869/S.289, Research Investment to Spark the Economy Act of 2021 (RISE ACT), Drug use research related issues H.R.1910, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.2366, Support, Treatment and Overdose Prevention of Fentanyl Act H.R.2405, Streamlining Research on Controlled Substances Act H.R.2430, To amend the Temporary Reauthorization and Study of Emergency Scheduling of Fentanyl Analogues Act to extend for one year the temporary order for fentanyl-related substances S.339, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.1006, Amend Controlled Substances Act to list fentanyl-related substances to Schedule I controlled substances Public Law 117-70, Extending Temporary Emergency Scheduling of Fentanyl Analogues Act, Drug use research related issues Cannabis Administration and Opportunity Act, Drug use research H.R.6184/S.3336, HALT Fentanyl Act, Drug use research related issues H.R.6946, SAFE Act of 2022, Drug use research related issues
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2022 · first_quarter · Health Issues
H.R.4502, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2022, Provisions relating to NIH, substance use research Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2023 Public Law 117-103, Consolidated Appropriations Act, FY2022 Public Law 117-86, Further Additional Extending Government Funding Act Barriers to research resulting from DEA scheduling, Drug research related issues S.253, Cannabidiol & Marijuana Research Expansion Act, Drug use research related issues H.R.5657, Medical Marijuana Research Act, Drug use research related issues H.R.869/S.289, Research Investment to Spark the Economy Act of 2021 (RISE ACT), Drug use research related issues H.R.1910, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.2366, Support, Treatment and Overdose Prevention of Fentanyl Act H.R.2405, Streamlining Research on Controlled Substances Act H.R.2430, To amend the Temporary Reauthorization and Study of Emergency Scheduling of Fentanyl Analogues Act to extend for one year the temporary order for fentanyl-related substances S.339, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.1006, Amend Controlled Substances Act to list fentanyl-related substances to Schedule I controlled substances Public Law 117-70, Extending Temporary Emergency Scheduling of Fentanyl Analogues Act, Drug use research related issues Cannabis Administration and Opportunity Act, Drug use research H.R.6184/S.3336, HALT Fentanyl Act, Drug use research related issues
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2021 · fourth_quarter · Health Issues
H.R.4502, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2022, Provisions relating to NIH, substance use research Barriers to research resulting from DEA scheduling, Drug research related issues S.253, Cannabidiol & Marijuana Research Expansion Act, Drug use research related issues Medical Marijuana Research Act, Drug use research related issues H.R.869/S.289, Research Investment to Spark the Economy Act of 2021 (RISE ACT), Drug use research related issues H.R.1910, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.2366, Support, Treatment and Overdose Prevention of Fentanyl Act H.R.2405, Streamlining Research on Controlled Substances Act H.R.2430, To amend the Temporary Reauthorization and Study of Emergency Scheduling of Fentanyl Analogues Act to extend for one year the temporary order for fentanyl-related substances S.339, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.1006, Amend Controlled Substances Act to list fentanyl-related substances to Schedule I controlled substances Public Law 117-70, Extending Temporary Emergency Scheduling of Fentanyl Analogues Act, Drug use research related issues Cannabis Administration and Opportunity Act, Drug use research H.R.6184, HALT Fentanyl Act, Drug use research related issues S.3336, HALT Fentanyl Act, Drug use research related issues
Client expense: Not reported · Firm income: $20,000
2021 · third_quarter · Health Issues
H.R.4502, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2022, Provisions relating to NIH, substance use research Barriers to research resulting from DEA scheduling, Drug research related issues S.253, Cannabidiol & Marijuana Research Expansion Act, Drug abuse research related issues Medical Marijuana Research Act, Drug abuse research related issues H.R.869/S.289, Research Investment to Spark the Economy Act of 2021 (RISE ACT), Drug abuse research related issues H.R.1910, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.2366, Support, Treatment and Overdose Prevention of Fentanyl Act H.R.2405, Streamlining Research on Controlled Substances Act H.R.2430, To amend the Temporary Reauthorization and Study of Emergency Scheduling of Fentanyl Analogues Act to extend for one year the temporary order for fentanyl-related substances S.339, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.1006, Amend Controlled Substances Act to list fentanyl-related substances to Schedule I controlled substances Public Law 117-12, Extending Temporary Emergency Scheduling of Fentanyl Analogues Act, Drug Abuse research related issues Cannabis Administration and Opportunity Act, Drug Abuse research
Client expense: Not reported · Firm income: $10,000
2021 · second_quarter · Health Issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2022, Provisions relating to NIH, substance use research Barriers to research resulting from DEA scheduling, Drug research related issues S.253, Cannabidiol & Marijuana Research Expansion Act, Drug abuse research related issues Medical Marijuana Research Act, Drug abuse research related issues H.R.869/S.289, Research Investment to Spark the Economy Act of 2021 (RISE ACT), Drug abuse research related issues H.R.1910, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.2366, Support, Treatment and Overdose Prevention of Fentanyl Act H.R.2405, Streamlining Research on Controlled Substances Act H.R.2430, To amend the Temporary Reauthorization and Study of Emergency Scheduling of Fentanyl Analogues Act to extend for one year the temporary order for fentanyl-related substances S.339, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.1006, Amend Controlled Substances Act to list fentanyl-related substances to Schedule I controlled substances Public Law 117-12, Extending Temporary Emergency Scheduling of Fentanyl Analogues Act, Drug Abuse research related issues
Client expense: Not reported · Firm income: $20,000
2021 · first_quarter · Health Issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2022, Provisions relating to NIH, substance use research Barriers to research resulting from DEA scheduling, Drug research related issues S.253, Cannabidiol & Marijuana Research Expansion Act, Drug abuse research related issues Medical Marijuana Research Act, Drug abuse research related issues H.R.869/S.289, Research Investment to Spark the Economy Act of 2021 (RISE ACT), Drug abuse related issues H.R.1910, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.2366, Support, Treatment and Overdose Prevention of Fentanyl Act H.R.2405, Streamlining Research on Controlled Substances Act H.R.2430, To amend the Temporary Reauthorization and Study of Emergency Scheduling of Fentanyl Analogues Act to extend for one year the temporary order for fentanyl-related substances S.339, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.1006, Amend Controlled Substances Act to list fentanyl-related substances to Schedule I controlled substances
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE